EKNL continues to shatter record after record and with MONSTER news out this morning not only catapult EKNL over $0.50 level to close at $0.538 up 41.76%, but it has prompted xtremepicks to upgrade their research report and price targets again and will be released this weekend
Belize City, Belize -- (SBWIRE) -- 10/15/2012 -- Publishers of daily penny stock newsletter xtremepicks (http://www.xtremepicks.com) looks at EKO International (EKNL:PINK)
EKO International Corp. – Reduction of number of authorized common shares PR Newswire(Mon 10:01AM EDT)
“Upon the achievement of a positive income statement and the repayment of its liabilities, the Company intends to initiate a program to buy-back common shares on the open market.”
Upgraded Research Report this weekend, on High ALERT for more updates
If investors missed Dr. Paul Ziemer SOLID exclusive interview with STT Radio this morning, it definitely set the tone today, it can watch it here:
STT RADIO Live Interview, Dr. Paul Ziemer
EKNL shattered another all time high closing solid in ‘blue sky territory’ and this locomotive is running on all cylinders!
As said this will be xtremepicks Trophy Winner for 2012, and EKNL is definitely showing it’s stuff and performing even better than their 2011 Trophy Winner Fuse Science ($DROP +83,000% gains)!
With news of a share buy back and authorization reduction to 75 Million shares, definitely the goal is for an uplisting to the big boards. Xtremepicks have seen this before with their other recent Medical Company monster LFVN which not only jumped from pennies to over $3, it uplisted onto the Nasdaq board - a definite possibility and goal for EKNL.
EKNL is getting real serious now, and with this new share buy back program, invesotrs are already seeing share inventory drying up super quick.
EKNL is now in full breakout mode closing at key breakout levels, ‘blue sky territory’, and the announced share buyback program which we can see well over $1 per share quickly.
About EKO International
EKO International Corp. is a holding company focused on growth through acquisition. Each acquisition must have substantial growth potential and is expected to add assets and/or cash-flow to the consolidated financial statements of the Company. The Company is willing to examine a variety of proposed target businesses and if interested, will negotiate terms and conditions of purchase favorable to itself.
About NeuroVasc Clinical Inc
NeuroVasc Clinical Inc. has brought a solution to the North American market place. The patented technology called FREMS is an FDA and Health Canada approved device that uses a patented electrical frequency and duty cycle to stimulate blood vessel re-growth and tissue regeneration in tissue that has compromised nerve and blood vessel function. The patient is treated 10 times once daily for 40 minutes and the effects on the tissue will last up to 18 month depending on the overall health of the patient. Thus this treatment becomes part of the maintenance of the lower limb for the diabetic patient as they age and will be a key player in the prevention of painful neuropathy and the development of dangerous wounds.
Keep your eyes peeled for the latest updates on our twitter page, facebook page, and our website at http://www.xtremepicks.com.
Xtremepicks.com team of excellence strives to find undervalued, good momentum stock plays. Xtremepicks.com provide market awareness services for small to mid-cap stocks with daily and special newsletters to keep informed of the latest movers. Xtremepicks.com penny stock newsletter is the trading connection and remember to always do research, use stop loss orders to protect, and book profits when in a position to do so. Xtremepicks.com penny stock newsletter profiles are not a solicitation or recommendation to buy, sell or hold securities and is not offering securities for sale. Verify all claims and do own due diligence. Xtremepicks did not receive any compensation for the distribution of this press release. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved.
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)